crocin and Insulin-Resistance

Polycystic ovary syndrome (PCOS) is a multifactorial reproductive condition common in women of reproductive age. Hyperlipidemia, insulin resistance, obesity, and chronic low-grade inflammation are associated with PCOS. In a clinical trial study, women with PCOS were divided into two groups (n = 25 each): the intervention group receiving crocin (15 mg, twice daily) and the control group receiving a placebo. The duration of intervention in both groups was 12 weeks. Pre- and postintervention, demographic information, lipid profile, fasting blood glucose (FBG), fasting insulin, and inflammatory markers (interleukin-6 [IL-6] and tumor necrosis factor-alpha [TNF-α]) were measured. Intervention with crocin significantly increased the mean high-density lipoprotein cholesterol postintervention compared to the placebo group, while exerting a suppressive effect on the increase in mean low-density lipoprotein cholesterol, triglycerides, and cholesterol levels. Intervention with crocin also exerted inhibitory effects on changes in FBG and insulin, so that crocin improved insulin and cardioprotective indices. Finally, despite the increased inflammatory markers (IL-6 and TNF-α) in the placebo group, crocin treatment had protective effects on their increased changes. Thus, crocin supplementation could be considered in the therapeutic targets of women with PCOS.

Topics: Biomarkers; Blood Glucose; Carotenoids; Cholesterol, HDL; Dietary Supplements; Double-Blind Method; Female; Humans; Inflammation; Insulin; Insulin Resistance; Interleukin-6; Polycystic Ovary Syndrome; Triglycerides; Tumor Necrosis Factor-alpha

Patients under methadone maintenance treatment (MMT) programs are susceptible to several complications including metabolic and clinical disorders. This study was designed to determine the effect of crocin supplementation on mental health parameters and metabolic profiles in subjects under MMT. The current randomized, double-blind, placebo-controlled, clinical trial was conducted among 53 patients under MMT to receive either 15 mg/day of crocin (n = 26) or placebo (n = 27) twice a day for 8 weeks. Crocin administration significantly decreased Beck Depression Inventory score (P = 0.01) and Beck Anxiety Inventory score (P = 0.008) compared with the placebo. In addition, crocin administration resulted in a significant reduction in fasting glucose (P = 0.003), insulin levels (P = 0.01), insulin resistance (P = 0.008), triglycerides (P = 0.001), very low-density lipoprotein (P = 0.001), total cholesterol levels (P = 0.03), and a significant increase in insulin sensitivity (.003) compared with the placebo. Additionally, crocin intake was associated with a significant reduction in high-sensitivity C-reactive protein (p < .001) and malondialdehyde (P = 0.001) and a significant rise in total antioxidant capacity levels (P = 0.01) compared with the placebo. The findings of this clinical trial indicate that taking crocin for 8 weeks by patients under MMT had beneficial effects on their mental health and improved their metabolic profiles.

Topics: Adult; Blood Glucose; Carotenoids; Dietary Supplements; Double-Blind Method; Female; Humans; Insulin Resistance; Lipids; Male; Methadone; Middle Aged; Opioid-Related Disorders

The aim of this study was to assess whether saffron aqueous extract (SAE) or its active constituent, crocin, prevents olanzapine-induced metabolic syndrome (MetS) and insulin resistance in patients with schizophrenia.. 66 patients diagnosed with schizophrenia who were on olanzapine treatment (5-20 mg daily) were randomly allocated to receive a capsule of SAE (n=22; 30 mg daily), crocin (n=22; 30 mg daily) or placebo (n=22) in a 12-week triple-blind trial. Patients were screened not to have MetS at baseline and further assessment was done at weeks 6 and 12. Measurement of fasting blood glucose (FBS) and serum lipids were repeated at weeks 2, 6 and 12. Fasting blood levels of insulin and HbA1c were also measured at baseline and week 12. HOMA-IR and HOMA-β were determined to evaluate insulin resistance.. 61 patients completed the trial and no serious adverse effects were reported. Time-treatment interaction showed a significant difference in FBS in both SAE and crocin groups compared to placebo (p=0.004). In addition, SAE could effectively prevent reaching the criteria of metabolic syndrome (0 patients) compared to crocin (9.1%) and placebo (27.3%) as early as week 6.. SAE could prevent metabolic syndrome compared to crocin and placebo. Furthermore, both SAE and crocin prevented increases in blood glucose during the study.

Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Carotenoids; Crocus; Double-Blind Method; Humans; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Olanzapine; Plant Extracts; Schizophrenia; Waist Circumference

Nephropathy is a serious complication of metabolic syndrome (MS), a global epidemic disorder. This study was undertaken to investigate the actions of diosmin and crocin, two natural ingredients, on diabetic nephropathy in a rat model of MS and the underlying mechanism(s). Metabolic syndrome was induced by the addition of 10% fructose to drinking water and placing the rats on high-salt diet for 16 weeks. Diosmin and Crocin were orally administrated daily for 10 weeks starting at week 6. At the end of study, arterial blood pressure was non-invasively recorded. Urine, serum and kidneys were collected for renal function, oxidative stress, glycemic parameters, inflammatory markers and histological analysis. Both Diosmin and Crocin improved insulin resistance, decreased blood pressure, uric acid, lipoproteins and blocked diabetic nephropathy as indicated by reduction of albumin excretion rate and albumin/creatinine ratio. They alleviated the impaired filtration in MS as indicated by increased creatinine clearance. They also ameliorated oxidative stress and the low-grade 1inflammation as indicated by reduction of serum TNF-α and inflammatory cells. These observations suggest that both Diosmin and Crocin alleviate metabolic syndrome and the associated nephropathy in rats, possibly, through inhibiting oxidative stress and inflammation.

Topics: Animals; Blood Glucose; Blood Pressure; Carotenoids; Diosmin; Drug Therapy, Combination; Glycation End Products, Advanced; Inflammation; Insulin; Insulin Resistance; Kidney Diseases; Kidney Glomerulus; Lipids; Male; Malondialdehyde; Metabolic Syndrome; Oxidative Stress; Rats, Wistar; Tumor Necrosis Factor-alpha; Uric Acid

Hyperglycemia is the main risk factor for microvascular complications in type 2 diabetes. Crocin and voluntary exercise have anti-hyperglycemic effects in diabetes. In this research, we evaluated the effects of crocin and voluntary exercise alone or combined on glycemia control and heart level of VEGF-A.. Animals were divided into eight groups as: control (con), diabetes (Dia), crocin (Cro), voluntary exercise (Exe), crocin and voluntary exercise (Cro-Exe), diabetic-crocin (Dia-Cro), diabetic-voluntary exercise (Dia-Exe), diabetic-crocin-voluntary exercise (Dia-Cro-Exe). Type 2 diabetes was induced by a high-fat diet (4 weeks) and injection of streptozotocin (STZ) (i.p, 35 mg/kg). Animals received oral administration of crocin (50 mg/kg) or performed voluntary exercise alone or together for 8 weeks. Oral glucose tolerance test (OGTT) was performed on overnight fasted control, diabetic and treated rats after 8 weeks of treatment. Then, serum insulin and heart VEGF-A protein levels were measured.. Crocin combined with voluntary exercise significantly decreased blood glucose levels (p < 0.001) and insulin resistance (HOMA-IR) (p < 0.001) compared to diabetic group. VEGF-A level was significantly (p < 0.01) lower in Dia group compared to control group. The combination of crocin and voluntary exercise significantly enhanced VEGF-A protein levels in Dia-Cro-Exe and Cro-Exe group compared to diabetic and control groups, respectively; p < 0.001 and p < 0.05.. Crocin combined with voluntary exercise improved insulin resistance (HOMA-IR) and reduced glucose levels in diabetic rats. Since both crocin and voluntary exercise can increase VEGF-A protein expression in heart tissue, they probably are able to increase angiogenesis in diabetic animals.

Topics: Animals; Biomarkers; Carotenoids; Combined Modality Therapy; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Glucose; Glucose Tolerance Test; Heart; Insulin Resistance; Male; Physical Conditioning, Animal; Rats; Rats, Wistar; Vascular Endothelial Growth Factor A

Crocin is the only water soluble carotenoid in nature, and it has a known powerful antioxidant activity. The aim of this work was to investigate the hypoglycemic and hypolipidemic effects of crocin in streptozotocin (STZ)-induced type 2 diabetic rats. Neonatal male Wistar rats (2-5 days old) were randomly divided into five groups. Three groups were intraperitoneally injected with STZ (90 mg/kg body weight). Among them, two groups were treated with intraperitoneal injection of crocin (50 or 100 mg/kg), and the third group was treated with vehicle only. Two control groups were also considered, and one of them was treated with crocin. After 5 months, their blood and urine samples were collected, and the animals were sacrified. The results indicate a significant lower body weight (P < 0.001) and abnormal parameters in the diabetic rats compared with the normal group. An administration of both doses of crocin significantly decreased the levels of serum glucose, advanced glycation end products, triglyceride, total cholesterol, and low-density lipoprotein and increased the high-density lipoprotein in the diabetic rats. The treatments were also effective in decreasing HbA1c and microalbuminuria, as well as homeostatic model assessment for insulin resistance as a measure of insulin resistance in the diabetic rats.

Topics: Albuminuria; Animals; Animals, Newborn; Blood Glucose; Body Weight; Carotenoids; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Glycation End Products, Advanced; Hypoglycemic Agents; Insulin Resistance; Lipoproteins, HDL; Lipoproteins, LDL; Male; Random Allocation; Rats; Rats, Wistar; Streptozocin; Triglycerides